OrthoPediatrics Corp is expected to report Q3 2026 revenue of $68.50 million and a consensus loss of $0.25 per share, with the stock currently trading at $24.44 compared to a $27.22 average analyst price target.
Investors are primarily focused on the execution of the company's "Innovation Super Cycle," specifically the performance of the high-growth Trauma and Deformity segment.
The company recently raised its full-year 2026 revenue guidance to a range of $265 million to $269 million following a robust second quarter where Trauma & Deformity revenue surged 26%. Market watchers are also monitoring progress toward achieving positive Adjusted EBITDA and improved free cash flow as the company scales its specialty bracing portfolio and new product launches.